> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Latest Federal Register Notices
- URL: https://www.fdaweb.com/latest-federal-register-notices-161/
- Published: 2018-01-07T12:00:00.000Z
- Updated: 2026-09-14T23:11:33.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5140437

[**Absorbable Perirectal Spacer Into Class 2**](https://www.fdaweb.com/absorbable-perirectal-spacer-into-class-2/)  
*Federal Register* notice: FDA classifies the absorbable perirectal spacer into Class 2 (special controls). 01/05/2018

[**Cervical Intraepithelial Neoplasia Tests Put Into Class 2**](https://www.fdaweb.com/cervical-intraepithelial-neoplasia-tests-put-into-class-2/)  
*Federal Register* notice: FDA classifies the cervical intraepithelial neoplasia (CIN) test system into Class 2 (special controls). 01/04/2018

[**Draft Guide on Certain Contraceptive Labeling**](https://www.fdaweb.com/draft-guide-on-certain-contraceptive-labeling/)  
*Federal Register* notice: FDA makes available a draft guidance on “Labeling for Combined Hormonal Contraceptives.” 01/03/2018

[**Pediatric Advisory Committee Meeting in March**](https://www.fdaweb.com/pediatric-advisory-committee-meeting-in-march/)  
*Federal Register* notice: FDA announces a 3/23 Pediatric Advisory Committee meeting. 01/03/2018

[**Draft Guide on Hypogonadotropic Hypogonadism Drugs**](https://www.fdaweb.com/draft-guide-on-hypogonadotropic-hypogonadism-drugs/)  
*Federal Register* notice: FDA makes available a draft guidance entitled “Establishing Effectiveness for Drugs Intended to Treat Male Hypogonadotropic Hypogonadism Attributed to Non-Structural Disorders.” 01/03/2018

[**Joint Advisory Committee to Review Pain Drug**](https://www.fdaweb.com/joint-advisory-committee-to-review-pain-drug/)  
*Federal Register* notice: FDA announces a joint Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee meeting 2/14\. 01/03/2018

[**Priority Review Voucher Issued to Spark Therapeutics**](https://www.fdaweb.com/priority-review-voucher-issued-to-spark-therapeutics/)  
*Federal Register* notice: FDA issues a priority review voucher to Spark Therapeutics for gaining BLA approval of Luxturna (voretigene neparvovec), an adeno-associated virus vector-based gene therapy indicated for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy. 01/03/2018